You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 9,266,957

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,266,957

Title:	Methods and materials for treating renal cell carcinoma and glioblastoma multiforme
Abstract:	This document provides methods and materials related to treating renal cell carcinoma. For example, methods and materials for assessing a cancer patient (e.g., a renal cell carcinoma patient) for tumor or peritumoral tissue containing CD14.sup.+ cells and proceeding with a cancer treatment option (e.g., a renal cell carcinoma treatment option) based on the presence, absence, or level of CD14.sup.+ cells present within the tumor or peritumoral tissue are provided.
Inventor(s):	Dietz; Allan B. (Chatfield, MN)
Assignee:	Mayo Foundation for Medical Education and Research (Rochester, MN)
Application Number:	13/509,089
Patent Claims:	1. A method for treating a human having renal cell carcinoma, wherein said method comprises: (a) determining that tumor or peritumoral tissue from said human having renal cell carcinoma contains greater than 15 percent of CD14.sup.+ cells, and (b) administering Sunitinib, Sorafenib, Bevacizumab, Temsirolimus, or Everolimus to said human having renal cell carcinoma. 2. The method of claim 1, wherein said renal cell carcinoma is clear cell renal cell carcinoma. 3. A method for treating a human having glioblastoma multiforme, wherein said method comprises: (a) determining that tumor or peritumoral tissue from said human having glioblastoma multiforme does not contain greater than 10 percent of CD14.sup.+ cells, and (b) administering temozolomide to said human having glioblastoma multiforme. 4. The method of claim 3, wherein said method comprises surgically removing said tumor from said human. 5. The method of claim 3, wherein said method comprises administering radiotherapy to said human. 6. The method of claim 3, wherein said method comprises surgically removing said tumor from said human and administering radiotherapy to said human.

Details for Patent 9,266,957

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004	⤷ Try a Trial	2029-11-10
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.